Certara posted third-quarter revenue of $94.9 million, up 4% year over year, as software revenue grew 11% to $48.8 million while services revenue fell 2% to $46.1 million. It narrowed 2026 revenue growth guidance to 2-3%.
CERT · Certara, Inc.
10 customers — 24% of revenue (the year ended December 31, 2025)
“Our ten largest customers accounted for 24% of revenues for the year ended December 31, 2025.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Certara reported third-quarter revenue growth of 4% and a net loss of $3.6 million, versus $4.8 million a year earlier. It completed the sale of its Regulatory and Medical Writing business on May 8, 2026, receiving $78.2 million by September 30, 2026.
Certara reported third-quarter revenue of $94.9 million, up 4%, and software revenue of $48.8 million, up 11%. It narrowed 2026 revenue growth guidance to 2% to 3% and adjusted diluted EPS guidance to $0.31 to $0.34.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Revenue grew 4%, software revenue grew 11%, software bookings grew 15%, and adjusted EBITDA margin improved to 31.8%; Certara also generated $30.7 million of operating cash and ended with $214.9 million in cash. Services revenue and bookings declined, adjusted net income decreased, GAAP losses persisted, operating expenses rose, and Phoenix Cloud conversions create a revenue headwind.
- + Adjusted EBITDA rose 6% and margin improved to 31.8% from 28.1% in the second quarter. new
- + Grant Peterson was appointed Chief Product Officer to accelerate growth across existing and new products. new
- + Certara won new FDA contracts and received a three-year SIMSIT research contract. new
- + Certara generated $30.7 million of cash from continuing operations and ended with $214.9 million in cash. new
- − Operating expenses increased $3.1 million, primarily due to reorganization, severance, and executive recruiting costs. new
- − Certara remained unprofitable on a GAAP basis, reporting a $3.6 million loss from continuing operations. new
- − Phoenix Cloud conversions create a revenue headwind. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings per share non-GAAP | $0.14 | six months ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | 52.88M | six months ended June 30, 2026 | — |
| Adjusted net income non-GAAP | 21.57M | six months ended June 30, 2026 | — |
| Average price per share repurchased under stock repurchase program | $5.46 | the three months ended June 30, 2026 filing | — |
| Net Retention Rates | 101.5% | Q2 2026 filing | — |
|
|
|||
| Services Bookings | $47.6M | the second quarter of 2026 | — |
| Share repurchase program repurchased in the second quarter | $17.4M | the second quarter | — |
| shares of its common stock repurchased | 3,194,975 | the three months ended June 30, 2026 filing | — |
| Shares tendered by employees for tax payments on RSU vesting | 585,391 | the three months ended June 30, 2026 filing | — |
| Software Bookings | $50.7M | the second quarter of 2026 | — |
| Total Bookings | $98.3M | the second quarter of 2026 | — |
|
|
|||
| Total Number of Shares Purchased | 3,780,366 | the three months ended June 30, 2026 filing | — |
| Year-to-date discontinued operations Revenue | $19.2M | year-to-date through the transaction closing on May 8, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CERT
this stock
Certara, Inc.
|
$1.76B | +31.3% | +8.7% | — | 16.7% |
|
VEEV
Veeva Systems Inc
|
$48.82B | +35.1% | +28.1% | 49.4 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$14.17B | +90.1% | +28.2% | 38.7 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$13.06B | +21.3% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 19
Certara reported third-quarter revenue growth of 4% and a net loss of $3.6 million, versus $4.8 million a year earlier. It completed the sale of its Regulatory and Medical Writing business on May 8, 2026, receiving $78.2 million by September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CERT | -4.0% | +23.5% | +122.1% | +5.0% | +31.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -6.6% | +24.6% | +121.6% | +5.2% | +20.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.